March 07, 2026 — 52 articles reviewed
This cycle was dominated by widespread coverage of preclinical research showing cannabinoids may combat fatty liver disease, alongside a cluster of state-level policy developments affecting patient access from Alabama to West Virginia. Significant clinical evidence also emerged on cognitive safety in older adults, anxiety relief from CBD-dominant products, and cannabis extracts for myofascial pain.
The liver disease research is genuinely exciting, the cognitive safety data is genuinely reassuring, and the policy landscape is genuinely messy. Our job as clinicians has not changed: follow the evidence, protect the patient, and insist that legal access comes with clinical infrastructure worthy of the people we serve.
Digest-Level Clinical Commentary
Clinical Reflection
The convergence of preclinical hepatic data with clinical cognitive safety findings in older adults suggests we’re moving toward a more nuanced risk-benefit framework in cannabis medicine, particularly for polypharmacy populations where drug interactions and liver metabolism are clinical concerns. While the fatty liver disease research remains preliminary, the emerging cognitive safety data in our aging demographic is clinically relevant since this population represents a growing proportion of my cannabis medicine consultations. These developments point toward a practice evolution where we can offer more evidence-informed counseling about both potential metabolic benefits and safety profiles, though we’ll need robust prospective trials before recommending cannabis specifically for NAFLD.
Clinical Perspective
Recent preclinical findings on cannabinoids and fatty liver disease, coupled with emerging clinical data on cognitive safety in older populations, suggest a measured expansion of the evidence base beyond traditional indications. The convergence of anxiety relief data with safety signals in vulnerable populations indicates that future clinical applications will likely depend on more rigorous stratification by age, liver function, and cognitive status. These developments reflect a shift toward evidence-based risk-benefit assessment rather than broad therapeutic claims.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
